GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » Profitability Rank

Ryvu Therapeutics (WAR:RVU) Profitability Rank : 3 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Ryvu Therapeutics Profitability Rank?

Ryvu Therapeutics has the Profitability Rank of 3. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Ryvu Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was -103.93%. As of today, Ryvu Therapeutics's Piotroski F-Score is 2.


Competitive Comparison of Ryvu Therapeutics's Profitability Rank

For the Biotechnology subindustry, Ryvu Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ryvu Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Profitability Rank falls into.



Ryvu Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Ryvu Therapeutics has the Profitability Rank of 3. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ryvu Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-22.456 / 21.606
=-103.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Ryvu Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Ryvu Therapeutics SA operating margin has been in a 5-year decline. The average rate of decline per year is -8.7%.

4. Consistency of the profitability

5. Predictability Rank


Ryvu Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Ryvu Therapeutics (WAR:RVU) Business Description

Traded in Other Exchanges
N/A
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics (WAR:RVU) Headlines

No Headlines